Adhera Therapeutics (QB) Stock Price - ATRX

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Adhera Therapeutics Inc (QB) ATRX OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.048 0.00 0.00 0.00 0.048 08:11:04
Bid Price Ask Price Spread Spread % News
0.046 0.05 0.004 8.0% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Adhera Therapeutics (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 521.74k 10.87M $ -16.75M - - 7.27M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
29.16k $ - 0.00% - -

more financials information »

Adhera Therapeutics (QB) News

Loading Messages....

Latest ATRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.090.090.03650.059006250,193-0.042-46.67%
1 Month0.09750.100.03650.06426620,449-0.0495-50.77%
3 Months0.150.1550.03650.085869125,270-0.102-68.0%
6 Months0.220.260.03650.110244516,744-0.172-78.18%
1 Year0.340.550.03650.19543714,440-0.292-85.88%
3 Years0.4950.550.03650.219643314,170-0.447-90.3%
5 Years0.4950.550.03650.219643314,170-0.447-90.3%

Adhera Therapeutics (QB) Description

Adhera Therapeutics, Inc. is an emerging specialty pharmaceutical company leveraging innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases. We are focused on fixed dose combination ("FDC") therapies in hypertension, with plans to expand the portfolio of drugs we commercialize to include other therapeutic areas. We began marketing Prestalia, a single-pill FDC of perindopril arginine inhibitor and amlodipine besylate, which was approved by the U.S. Food and Drug Administration in June of 2018. Prestalia is distributed through the DyrectAxess platform which we acquired in 2017. DyrectAxess is a patented technology platform, also known as Total Care, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to achieve optimal care. By combining Prestalia, DyrectAxess, and a specialty pharma network, we have created a proprietary platform for drug adherence and the effective treatment of hypertension, improving the distribution of FDC hypertensive drugs, such as Prestalia, devices for therapeutic drug monitoring, as well as patient counseling and prescription reminder services.


Your Recent History
USOTC
ATRX
Adhera The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.